Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Next Previous
X
Search
Trial Profile

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Razuprotafib (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms TIME-2b
  • Sponsors Aerpio Pharmaceuticals; EyePoint Pharmaceuticals

    • Most Recent Events

    • 24 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 02 May 2019 Data from TIME-2 and TIME-2b presented in an Aerpio Pharmaceuticals Media Release.
    • 02 May 2019 According to an Aerpio Pharmaceuticals media release, data from TIME-2 and TIME-2b were presented at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top